BioInvent International AB's total inventories for the quarter that ended in Mar. 2026 was kr11.5 Mil. BioInvent International AB's average total inventories from the quarter that ended in Dec. 2025 to the quarter that ended in Mar. 2026 was kr11.9 Mil.
In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. BioInvent International AB's Net-Net Working Capital per share for the quarter that ended in Mar. 2026 was kr6.00.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Inventory Turnover measures how fast the company turns over its inventory within a year.
BioInvent International AB's Inventory Turnover for the quarter that ended in Mar. 2026 was 0.00.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
BioInvent International AB's Inventory-to-Revenue for the quarter that ended in Mar. 2026 was 0.89.
BioInvent International AB (LTS:0H22) Total Inventories Explanation
Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.
1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.
BioInvent International AB's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2026 is
4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
BioInvent International AB's Inventory to Revenue for the quarter that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.
When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.
Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.
BioInvent International AB Total Inventories Related Terms
BioInvent International AB Total Inventories Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioInvent International AB Total Inventories Chart
BioInvent International AB Total Inventories Calculation
Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.
BioInvent International AB (LTS:0H22) has a Total Inventories of kr11.5 Mil as of Mar. 2026. The total amount of inventory as recorded on a company's balance sheet. View historical data for BioInvent International AB and its competitors.
Is BioInvent International AB's Total Inventories too high?
BioInvent International AB's current Total Inventories is kr11.5 Mil. Overall, BioInvent International AB has a GF Score™ of 48/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does BioInvent International AB's Total Inventories compare to VRTX and REGN?
BioInvent International AB's Total Inventories of kr11.5 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Inventories for a Biotechnology company?
A good Total Inventories depends on the Biotechnology industry context. However, Total Inventories should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Inventories mean?
A high Total Inventories can signal that a stock is expensive relative to its fundamentals. The total amount of inventory as recorded on a company's balance sheet. View historical data for BioInvent International AB and its competitors. BioInvent International AB's current Total Inventories is kr11.5 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioInvent International AB stock overvalued right now?
Based on GuruFocus' analysis, BioInvent International AB (LTS:0H22) is currently considered Possible Value Trap. The stock's GF Value™ is kr48.64, compared to a current price of kr23.63 — trading 51.4% below its estimated fair value. The current Total Inventories is kr11.5 Mil. BioInvent International AB's overall GF Score™ is 48/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Inventories calculated?
Total Inventories is calculated from a company's financial statements. For BioInvent International AB (LTS:0H22), the current Total Inventories is kr11.5 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioInvent International AB (LTS:0H22) Overvalued in 2026?
Based on GuruFocus' analysis, BioInvent International AB stock appears to be undervalued.
The current stock price of kr23.63 is trading 51.4% below its estimated GF Value™ of kr48.64.
GuruFocus considers BioInvent International AB to be Possible Value Trap.
Key valuation signals for LTS:0H22:
Total Inventories: kr11.5 Mil
GF Value™: kr48.64 vs. price of kr23.63 (51.4% below fair value)
No single metric tells the full story. See the LTS:0H22 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioInvent International AB is a clinical-stage biotech company. It discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently four drug candidates in five ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors, respectively. The company's validated, proprietary F.I.R.S.T technology platform identifies both targets and the antibodies that bind to them, generating many new drug candidates to fuel the company's clinical development pipeline and providing licensing and partnering opportunities. The company's pipeline portfolio comprises BI-1206, an antagonistic blocking antibody for the treatment of non-Hodgkin's lymphoma, and BI-1808 and BI-1910 (anti-TNFR2) for solid cancers.
48GF Score
Get the complete analysis for LTS:0H22
Total Inventories is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0H22 has been successfully added to your 
